Literature DB >> 30116602

Development and application of bioluminescence imaging for the influenza A virus.

Weiqi Pan1, Ji Dong1, Peihai Chen2,3, Beiwu Zhang2, Zhixia Li2, Ling Chen1,2.   

Abstract

Influenza A viruses (IAVs) cause seasonal epidemics and intermittent pandemics which threaten human health. Conventional assays cannot meet the demands for rapid and sensitive detection of viral spread and pathogenesis in real time cannot be used for high-throughput screens of novel antivirals. Bioluminescence imaging (BLI) has emerged as a powerful tool in the study of infectious diseases in animal models. The advent of influenza reverse genetics has enabled the incorporation of bioluminescent reporter proteins into replication-competent IAVs. This review briefly describes the current development and applications of bioluminescence in the study of viral infections and antiviral therapeutics for IAVs. BLI is expected to substantially accelerate the basic and applied research of IAV both in vitro and in vivo.

Entities:  

Keywords:  Bioluminescence imaging (BLI); influenza A virus (IAV); luciferase; replication-competent

Year:  2018        PMID: 30116602      PMCID: PMC6072922          DOI: 10.21037/jtd.2018.02.35

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  54 in total

1.  The packaging signal of influenza viral RNA molecules.

Authors:  S Tchatalbachev; R Flick; G Hobom
Journal:  RNA       Date:  2001-07       Impact factor: 4.942

Review 2.  [Determination of biological substances using bioluminescent reaction based on luciferin-luciferase].

Authors:  Masako Maeda
Journal:  Rinsho Byori       Date:  2004-07

3.  Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging.

Authors:  Glenn A Marsh; Raúl Rabadán; Arnold J Levine; Peter Palese
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

4.  In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies.

Authors:  Nicholas S Heaton; Victor H Leyva-Grado; Gene S Tan; Dirk Eggink; Rong Hai; Peter Palese
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

5.  Genome rearrangement of influenza virus for anti-viral drug screening.

Authors:  Troy C Sutton; Adebimpe Obadan; Johanna Lavigne; Hongjun Chen; Weizhong Li; Daniel R Perez
Journal:  Virus Res       Date:  2014-05-12       Impact factor: 3.303

6.  Influenza A virus encoding secreted Gaussia luciferase as useful tool to analyze viral replication and its inhibition by antiviral compounds and cellular proteins.

Authors:  Nadine Eckert; Florian Wrensch; Sabine Gärtner; Navaneethan Palanisamy; Ulrike Goedecke; Nils Jäger; Stefan Pöhlmann; Michael Winkler
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

7.  Luciferin detection after intranasal vector delivery is improved by intranasal rather than intraperitoneal luciferin administration.

Authors:  Suzanne M K Buckley; Steven J Howe; Ahad A Rahim; Hildegard Buning; Jenny McIntosh; Suet-Ping Wong; Andrew H Baker; Amit Nathwani; Adrian J Thrasher; Charles Coutelle; Tristan R McKay; Simon N Waddington
Journal:  Hum Gene Ther       Date:  2008-10       Impact factor: 5.695

8.  Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein.

Authors:  M D Ryan; J Drew
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

9.  New world bats harbor diverse influenza A viruses.

Authors:  Suxiang Tong; Xueyong Zhu; Yan Li; Mang Shi; Jing Zhang; Melissa Bourgeois; Hua Yang; Xianfeng Chen; Sergio Recuenco; Jorge Gomez; Li-Mei Chen; Adam Johnson; Ying Tao; Cyrille Dreyfus; Wenli Yu; Ryan McBride; Paul J Carney; Amy T Gilbert; Jessie Chang; Zhu Guo; Charles T Davis; James C Paulson; James Stevens; Charles E Rupprecht; Edward C Holmes; Ian A Wilson; Ruben O Donis
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

Review 10.  Animal models for influenza virus pathogenesis, transmission, and immunology.

Authors:  Rajagowthamee R Thangavel; Nicole M Bouvier
Journal:  J Immunol Methods       Date:  2014-04-04       Impact factor: 2.303

View more
  2 in total

1.  Notch1/TAZ axis promotes aerobic glycolysis and immune escape in lung cancer.

Authors:  Mian Xie; Xin-Ge Fu; Ke Jiang
Journal:  Cell Death Dis       Date:  2021-09-04       Impact factor: 8.469

2.  Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts.

Authors:  Aleksey M Nagornykh; Marina A Tyumentseva; Aleksandr I Tyumentsev; Vasiliy G Akimkin
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.